Clinical trials: Classical Hodgkin Lymphoma
Leukemia, Myelodysplastic Syndrome
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
This is a pilot study which will be done in a small number of patients. The purpose of this study is to test the safety and benefit of giving a type of chemotherapy - cyclophosphamide - after the transplant to prevent graft…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02360111
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
HODGKIN LYMPHOMA
Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)
The purpose of this multicenter clinical trial is to assess the clinical impact of dose intensification performed very early during treatment in a subset of poor prognosis, advanced-stage Hodgkin Lymphoma patients, defined as…
- Trial name
- HD0607 (NCT00795613)
- Testing
- ESCALATED BEACOPP, CONVENTIONAL ABVD
- Where
- 24 sites in Israel, Italy
- Volunteers
- 450 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Solid Tumor, Classic Hodgkin Lymphoma
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
This is an open-label, multicenter, phase 1b/2 trial of IMM01 (SIRPα Fc) plus tislelizumab in patients with advanced solid tumors and lymphomas.
- Trial name
- NCT05833984
- Testing
- IMM01, Tislelizumab
- Where
- 5 sites in China
- Volunteers
- 309 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Hodgkin Lymphoma
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and…
- Trial name
- NCT05922904
- Testing
- Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
This is a modular dose confirmation and expansion study. The core study design is to assess the efficacy of AZD4573, administered as monotherapy or combination therapy, to participants with either r/r PTCL or r/r cHL and to…
- Trial name
- NCT05140382
- Testing
- AZD4573
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Hodgkin Lymphoma
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
- Trial name
- NCT07641010
- Testing
- PD-1+JAK1i, PD-1
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hodgkin Lymphoma
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or…
- Trial name
- NCT01022996
- Testing
- Everolimus (RAD001)
- Where
- 16 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin…
- Trial name
- NCT07572123
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection
- Volunteers
- 374 people
- Sponsor
- National Cancer Institute (NCI)
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor.
- Trial name
- NCT06393361
- Testing
- Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin, anti-PD-1 antibody.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has…
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder
- Trial name
- NCT02153580
- Testing
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- City of Hope Medical Center
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in treating patients with relapsed or refractory T-cell non-Hodgkin lymphoma or Hodgkin lymphoma.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT02168140
- Testing
- 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Classical Hodgkin Lymphoma
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
The study is to evaluate the efficacy of KL-A167 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification
- Trial name
- NCT03580564
- Testing
- KL-A167
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
This phase II trial studies how well nivolumab and brentuximab vedotin work in treating older patients with untreated Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma
- Trial name
- NCT02758717
- Testing
- Brentuximab Vedotin, Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- Academic and Community Cancer Research United
Hodgkin Lymphoma
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical…
- Trial name
- NCT06812858
- Testing
- Nivolumab, Pembrolizumab
- Where
- 4 sites in Kazakhstan, Russia
- Volunteers
- 83 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Peripheral T-cell Lymphoma
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.
- Trial name
- NCT04480125
- Testing
- Azacitidine, Chidamide
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Hodgkin Lymphoma
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
The FIL-Rouge is a randomized, open-label, multicenter, phase III, 2-arm study. The primary objective is to compare efficacy and tolerability of the intensified variant 'dose-dense/dose-intense ABVD' (ABVD DD-DI) with an interim…
- Trial name
- NCT03159897
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 46 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin]…
- Trial name
- NCT01712490
- Testing
- brentuximab vedotin, doxorubicin, bleomycin
- Where
- 215 sites in United States, Australia and 19 more
- Volunteers
- 1,334 people
- Sponsor
- Takeda
T Cell Lymphoma
Allo-HSCT as First-line Consolidation in High-risk PTCL
Results of conventional therapy in patients with peripheral T-cell lymphoma(PTCL) are poor. Allogeneic hematopoietic stem cell transplantation(allo-HSCT) gave excellent results in PTCL after failure of conventional therapy and in…
- Trial name
- NCT03672084
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Hodgkin's Lymphoma
The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD
The objective of the study is evaluation of efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) salvage therapy with autologus stem cell transplantation (ASCT) consolidation in advanced classical Hodgkin lymphoma patients…
- Trial name
- BURGUND (NCT03615664)
- Testing
- Bendamustine, Gemcitabine, Dexamethasone
- Where
- 13 sites in Poland
- Volunteers
- 115 people
- Sponsor
- Polish Lymphoma Research Group
Hodgkin Lymphoma, Hodgkin Disease
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic…
- Conditions
- Hodgkin Lymphoma, Hodgkin Disease, Advanced Hodgkin Lymphoma
- Trial name
- FINISH-HL (NCT07209059)
- Testing
- Nivolumab, N-EACOPD-14, N-AVD
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- National Research Center for Hematology, Russia